U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06375161) titled 'Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients' on April 16.
Brief Summary: This study is a single-center, open-label, single-dose clinical trial of anti-CD19-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after Qinglin pre-treatment.
In this study phase, a traditional "3+3" trial design is employed for dose escalation.
Study Type: Interventional
Condition: B Cell Malignancies
Intervention: Biological: anti-CD19-CAR-T cells
Before cell infusion, Investigator may decide, based on necessity, whether to administer prophylactic medication, which may include options such as acetaminophen and dip...